Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GRN | P28799 | 1/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699062 | 0.86 | MAPK14 (0.61) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL23928422 | 0.85 | HDAC3 (0.47) | CDK8MAPK14MAPTLMNAMAPK13 | |
| SCHEMBL7112019 | 0.84 | MAPK14 (0.63) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL15069910 | 0.83 | MAPK14 (0.51) | CDK8MAPK14MAPTLMNAMAPK13 | |
| SCHEMBL1465671 | 0.83 | MAPK14 (0.62) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL9892358 | 0.83 | CNR2 (0.59) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL4139014 | 0.80 | CNR2 (0.56) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL9891930 | 0.80 | MAPK14 (0.56) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL19303194 | 0.77 | CDK8 (1.00) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5164195 | 0.77 | CDK8 (0.80) | CDK8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262801-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | MONDEGO BIO, LDA. (PT) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262801-A1 | COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES | PPM1A, TH, PPM1G | CDK8 365/4885MAPK14 787/4885MAPT 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.